A carregar...
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory settin...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5894261/ https://ncbi.nlm.nih.gov/pubmed/29610115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015263 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|